The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2.
about
Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting AntiviralsEpidemiology of hepatitis C in GreeceHepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in EuropeHepatitis C virus infection.Global epidemiology and burden of HCV infection and HCV-related disease.Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypesIndian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015Current and Future Burden of Chronic Nonmalignant Liver DiseasePrevalence and knowledge of hepatitis C in a middle-aged population, Dunedin, New ZealandHepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study.Clinical impact of alcohol-related cirrhosis in the next decade: estimates based on current epidemiological trends in the United States.Hepatitis C virus infection: Are there still specific problems with genotype 3?Language support for linguistic minority chronic hepatitis B/C patients: an exploratory study of availability and clinicians' perceptions of language barriers in six European countriesHepatitis C virus infection in Argentina: Burden of chronic disease.Incident Hepatitis C Virus Genotype Distribution and Multiple Infection in Australian PrisonsHepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals.Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis.Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy.Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies.Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment.Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece.Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study.The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - volume 3.Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 3.Protective T Cell and Antibody Immune Responses against Hepatitis C Virus Achieved Using a Biopolyester-Bead-Based Vaccine Delivery System.Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?Chronic hepatitis C virus infection in India: Regional demographics and distribution of viral genotypes.Evaluation of liver enzyme levels and identification of asymptomatic liver disease patients in primary care.Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection.Strategies to manage hepatitis C virus infection disease burden - volume 3.Estimating HCV disease burden - volume 3 (editorial).Estimates on HCV disease burden worldwide - filling the gaps.Factors associated with hepatitis C prevalence differ by the stage of liver fibrosis: A cross-sectional study in the general population in Poland, 2012-2016.Comment on Nuño Solinís R, et al. "Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence".Historical epidemiology of hepatitis C virus in select countries-volume 4.Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving elimination.Estimating HCV disease burden-volume 4 (editorial).Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups.The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up.Epidemiology and Elimination of HCV-Related Liver Disease
P2860
Q26747561-45869319-98F3-4E34-9CD3-229646150766Q28074447-791B0BD2-6636-47D4-AA2E-426280A6EC24Q28079580-1A0053E7-0135-459C-B645-52A49E5708D5Q30235491-87DA290E-AC94-43A7-A7C0-37F94AAA5A9FQ30240220-8F26F674-CD9C-4BF6-B095-2B1836F67D95Q30245058-E343BBDA-C38B-482A-B983-22EDE2CA32F8Q30375305-D97A7728-8AA2-42C4-B50A-FE7D333E3FA0Q34490300-52455DAF-691F-4741-A4B3-13202F1462A6Q36067623-C2F73684-06CD-4BE7-838E-8CCAF6EC6A55Q36192804-AD0B5C78-9B02-436B-BE0A-D771C9018261Q36219877-292FF5C7-91EE-403E-90B8-752F274521BAQ36269670-B9E664C0-7146-4178-911E-74C6312726DFQ36285699-F42E4DE1-4C5A-41DF-8D0C-5C4DCCA191B5Q36924982-0394B298-33DE-4AA6-85F5-8FC243D7EF61Q37040556-1CD08532-D8CE-4818-948A-B2E880D40A06Q37735774-F9EC234F-65D1-4932-A06D-537F9195D53AQ38540088-B5190CEE-289B-47A2-9CEF-8A10DE08A441Q38790455-81E01B08-950A-471F-A894-109CD26138CBQ38800572-5CBC0283-33A9-4DC0-BCB6-3C80D15976E9Q38838703-5188F7BD-5417-4D35-9859-48F82A4F95BBQ38842781-2DB56A69-05FD-4FC8-81D6-D13AD3188297Q38931620-3ED4B166-DA93-47D6-BCCD-C23B6896ED61Q38948615-E842BC6B-3915-404A-855A-BFC19E4E5440Q38948620-C7B7E2ED-DDDA-44AA-A2CE-3CD44D53A59AQ39860495-D5847A06-41F3-4D56-80F6-7769D4B6F0BEQ40364008-C328C236-4B09-43A6-90FC-25F19D5B4D58Q40451958-F262141B-F029-4D2D-B858-DD7196C0151CQ40535279-23DDCDDD-63E6-4880-80D1-027069FF009AQ40720542-3FF738F4-8726-428A-84A6-14959EAC1DC0Q40932583-1FAAED86-947C-4F5E-AE30-70F367E47D64Q40932598-AEDCB425-DD4B-47A6-93D5-B50C1AAA3BA2Q41562313-BF2A8812-2922-4F3B-8603-06B461CD7914Q41933668-C869E813-79BF-4FD8-A9B4-BF6BCFADAC55Q42345870-425D1019-1A76-40EF-9566-9AF5D8DC47BCQ45325255-E965E0F7-DF12-40D4-AA67-D95395D97AE1Q47197986-CD714B45-2DF1-41CC-ACFD-9ED8D5A59F07Q47589992-E22244DD-5739-4378-990E-9FE774A0161EQ49988168-5D783FF1-4A1F-401A-A4C6-DCC3FBCE6AA7Q52660642-EA3B47CC-4E08-42B9-ADF2-02EB38F4FA0BQ57297223-708E41D0-0049-43BB-B738-C3977CE0F5E7
P2860
The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The present and future disease ...... treatment paradigm - volume 2.
@en
type
label
The present and future disease ...... treatment paradigm - volume 2.
@en
prefLabel
The present and future disease ...... treatment paradigm - volume 2.
@en
P2093
P2860
P50
P356
P1476
The present and future disease ...... treatment paradigm - volume 2
@en
P2093
A C Gadano
A Hatzakis
A J van der Meer
A Rakhmanova
A Shevaldin
C Henderson
C R Brunton
P2860
P356
10.1111/JVH.12351
P478
22 Suppl 1
P50
P577
2015-01-01T00:00:00Z